Smartleaf Asset Management LLC Buys 1,265 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Smartleaf Asset Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 11.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 12,604 shares of the company’s stock after buying an additional 1,265 shares during the period. Smartleaf Asset Management LLC owned 0.18% of Global X Genomics & Biotechnology ETF worth $122,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Oxinas Partners Wealth Management LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $103,000. Sanctuary Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $104,000. Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $122,000. Centaurus Financial Inc. lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 7.0% during the 3rd quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock worth $169,000 after acquiring an additional 985 shares during the period. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $205,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ:GNOM opened at $9.14 on Friday. The company has a market cap of $61.15 million, a price-to-earnings ratio of -3.91 and a beta of 1.17. The firm has a 50 day simple moving average of $9.80 and a 200 day simple moving average of $10.43. Global X Genomics & Biotechnology ETF has a one year low of $8.64 and a one year high of $12.20.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.